Rocket Pharmaceuticals (RCKT) Operating Leases (2019 - 2025)
Historic Operating Leases for Rocket Pharmaceuticals (RCKT) over the last 7 years, with Q3 2025 value amounting to $2.8 million.
- Rocket Pharmaceuticals' Operating Leases fell 1919.13% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 1919.13%. This contributed to the annual value of $3.3 million for FY2024, which is 958.63% up from last year.
- According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Operating Leases is $2.8 million, which was down 1919.13% from $2.9 million recorded in Q2 2025.
- Rocket Pharmaceuticals' 5-year Operating Leases high stood at $3.7 million for Q1 2024, and its period low was $492000.0 during Q3 2022.
- Its 5-year average for Operating Leases is $2.2 million, with a median of $2.9 million in 2025.
- Per our database at Business Quant, Rocket Pharmaceuticals' Operating Leases plummeted by 4478.11% in 2022 and then surged by 50772.36% in 2023.
- Quarter analysis of 5 years shows Rocket Pharmaceuticals' Operating Leases stood at $905000.0 in 2021, then increased by 20.22% to $1.1 million in 2022, then skyrocketed by 173.25% to $3.0 million in 2023, then rose by 9.59% to $3.3 million in 2024, then decreased by 15.35% to $2.8 million in 2025.
- Its Operating Leases stands at $2.8 million for Q3 2025, versus $2.9 million for Q2 2025 and $3.1 million for Q1 2025.